E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Træthed og andre symptomer hos patienter med freskreden kræft i palliativ fase |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10033372 |
E.1.2 | Term | Pain and discomfort NEC |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10016258 |
E.1.2 | Term | Fatigue management |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10022437 |
E.1.2 | Term | Insomnia |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003028 |
E.1.2 | Term | Appetite lost |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012378 |
E.1.2 | Term | Depression |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
At undersøge effekten af melatonin på træthed hos patienter med fremskreden kræft.
|
|
E.2.2 | Secondary objectives of the trial |
At undersøge effekten af melatonin på symptomerne søvnproblemer, appetitløshed, depression og smerter, samt på overordnet livskvalitet, hos patienter med fremskreden kræft.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Undersøgelsen består af to dele (del I og del II). I undersøgelsens del I undersøges om én uges behandling med melatonin har en mere positiv effekt end placebo på de nævnte parametre. I undersøgelsens del II undersøges det, om effekten af melatonin forøges over tid på de nævnte parametre. |
|
E.3 | Principal inclusion criteria |
1) Svaret ’en del’ eller ’meget’ på EORTC QLQ-C15-PAL spørgsmålet ”I den forløbne uge: Var du træt” 2) Histologisk verificeret kræft i palliativ fase 3) Skriftligt informeret samtykke 4) Over 18 år
|
|
E.4 | Principal exclusion criteria |
1) Ikke i stand til at forstå og vurdere information eller til at udfylde et spørgeskema 2) Ubehandlet anæmi, dvs. Hb<=6,0 mmol/L 3) Ubehandlet hypercalcæmi 4) Systolisk blodtryk <100 5) I behandling med coumadin (se afsnit om farmakologiske interaktioner) 6) Har modtaget varierende doser af Ritalin, Corticorstereoider og sovepiller i de seneste 2 uger. 7) TSH <0.50 eller >5.50 mcL/mL 8) Gravid eller ammende*
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Det primære effektmål er træthed. Sekundære effektmål er søvnproblemer, appetitløshed, depression, smerter, og overordnet livskvalitet |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Undersøgelsen har også en del 2, som ikke er randomiseret |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Undersøgelsen afsluttes når 50 patienter har fuldført undersøgelsens del I. En patient har fuldført undersøgelsen, hvis han/hun i overensstemmelse med randomiseringen har modtaget placebo i en uge og melatonin i en anden uge, og i disse uger spist mindst 5 af de 7 udleverede piller. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |